PMID- 19635197
OWN - NLM
STAT- MEDLINE
DCOM- 20110713
LR  - 20150313
VI  - 28
IP  - 6
DP  - 2009 Jun
TI  - [Construction of genetically modified dendritic cell vaccine expressing bcr/abl 
      fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in 
      vitro].
PG  - 602-6
AB  - BACKGROUND AND OBJECTIVE: Specific immunological effect mediated by T lymphocytes 
      plays an important role in treating chronic myelocytic leukemia (CML). Dendritic 
      cells (DCs)-based immunotherapy has become popular in treating tumors. This study 
      was to construct DC vaccines by transducing with replication-defective 
      recombinant adenoviruses expressing bcr/abl fusion gene of CML, observe the 
      lethal effects of specific cytotoxic T lymphocytes (CTLs) triggered by 
      genetically modified DC vaccines expressing bcr/abl fusion gene against K562 
      cells in vitro. METHODS: DNA fragment of bcr/abl fusion gene was amplified by 
      reverse transcription-polymerase chain reaction (RT-PCR) to construct a 
      recombinant adenovirus vector and produce recombinant adenoviruses. DCs were 
      induced from peripheral blood monocytes in vitro, and transfected with 
      recombinant adenoviruses or pulsed with peptide to induce specific CTLs. The 
      lethal effect of CTLs against leukemic K562 cells in vitro was observed. RESULTS: 
      We successfully constructed the replication-defective recombinant adenoviral 
      vector expressing bcr/abl fusion gene. The recombinant adenoviruses we produced 
      had a high virus titer of 2.0 x 10(10) pfu/mL. Transfection efficiency of DCs in 
      vitro was 50%-60%. DC vaccines expressing bcr/abl fusion gene were successfully 
      prepared and used to induce specific CTLs. With effector:target cell ratios of 
      40:1 and 20:1, the killing rates of K562 cells by CTLs were (47.6+/-4.7)% and 
      (47.5+/-1.6)% in genetically modified DCs group, (25.8+/-4.4)% and (24.6+/-6.3)% 
      in peptide-pulsed DCs group, and were (5.7+/-1.3)% and (4.5+/-1.6)% in control 
      DCs group. The differences between every two groups were significant (all 
      P<0.05). CONCLUSION: Genetically modified DC vaccine expressing bcr/abl fusion 
      gene has a stronger contribution than peptide-pulsed DCs in triggering specific 
      CTLs against K562 cells.
FAU - Wang, Wen-Wen
AU  - Wang WW
AD  - Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, 510630, P.R. China.
FAU - Huang, Ren-Wei
AU  - Huang RW
FAU - Hu, Yuan
AU  - Hu Y
FAU - Li, Xu-Dong
AU  - Li XD
FAU - Wang, Dong-Ning
AU  - Wang DN
FAU - He, Yi
AU  - He Y
FAU - Liu, Jia-Jun
AU  - Liu JJ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (Cancer Vaccines)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Cancer Vaccines/*immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology/metabolism
MH  - Fusion Proteins, bcr-abl/genetics/*immunology/metabolism
MH  - *Genes, abl
MH  - Humans
MH  - K562 Cells
MH  - Plasmids
MH  - T-Lymphocytes, Cytotoxic/cytology/*immunology
MH  - Transfection
EDAT- 2009/07/29 09:00
MHDA- 2011/07/14 06:00
CRDT- 2009/07/29 09:00
PHST- 2009/07/29 09:00 [entrez]
PHST- 2009/07/29 09:00 [pubmed]
PHST- 2011/07/14 06:00 [medline]
AID - 1000-467X200906602 [pii]
PST - ppublish
SO  - Ai Zheng. 2009 Jun;28(6):602-6.